Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.

Minjong LeeGoh Eun ChungJeong-Hoon LeeSohee OhJoon Yeul NamYoung ChangHyeki ChoHongkeun AhnYoung Youn ChoJeong-Ju YooYuri ChoDong Hyeon LeeEun Ju ChoSu Jong YuDong Ho LeeJeong Min LeeYoon Jun KimJung-Hwan Yoon

Published in: Hepatology (Baltimore, Md.) (2017)

Antiplatelet therapy reduces the risk of HCC in chronic hepatitis B patients whose hepatitis B virus is effectively suppressed. However, antiplatelet therapy containing clopidogrel may increase the risk of bleeding. (Hepatology 2017;66:1556-1569).

Keyphrases

antiplatelet therapy
hepatitis b virus
acute coronary syndrome
percutaneous coronary intervention
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
coronary artery disease
patient reported outcomes
combination therapy